Possible acute rejection associated with the use of the new anti-hepatitis C virus medications
| Autor: | Khaled Ar Karkout, Yousef Boobes, Qutaiba Hussein, Alia Albawardi, Saleema Al Sherif |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
kidney transplant
medicine.medical_specialty Daclatasvir Sofosbuvir direct-acting antiviral agents Hepatitis C virus 030232 urology & nephrology Case Report medicine.disease_cause Kidney transplant sofosbuvir Virus 03 medical and health sciences 0302 clinical medicine Internal medicine medicine In patient daclatasvir biology business.industry anti-hepatitis C virus medication Renal transplant biology.protein Medicine Acute rejection 030211 gastroenterology & hepatology Antibody business medicine.drug |
| Zdroj: | Avicenna Journal of Medicine Avicenna Journal of Medicine, Vol 9, Iss 01, Pp 32-34 (2019) |
| ISSN: | 2249-4464 2231-0770 |
| Popis: | Hepatitis C virus infection is associated with increased morbidity and mortality. It remains a major challenge for management and treatment, especially in patients with renal transplant. The new directacting antiviral agents gave big hopes to both clinicians and patients that they can overcome this challenge without major side effects. Studies recently have supported this claim; however, they are still few, limited, and may give false hopes. In the following case report, we present a case, supported by histological evidence about a possible acute rejection of kidney transplant after treatment with these new medications. This case is limited by the absence of donorspecific antibodies. This report is aimed to increase awareness about the urgent need for further studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|